{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:46:58Z","timestamp":1778600818522,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11912-025-01648-4","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T09:49:33Z","timestamp":1739353773000},"page":"225-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cell-free Tumor DNA: a Promising Technology for Diagnosis, Surveillance and Therapeutic Decision in Urothelial Carcinoma of the Bladder"],"prefix":"10.1007","volume":"27","author":[{"given":"Lucas Motta","family":"Martinez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena Cristina S\u00e3o Le\u00e3o","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Gilles","family":"Guidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caio Mazzonetto Teofilo","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catharina Ribeiro","family":"Lyra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Liebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius Henrique Almeida","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard Dobrucki","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Schenk","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caio Vinicius","family":"Suartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William Carlos","family":"Nahas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leopoldo Alves","family":"Ribeiro-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"1648_CR1","doi-asserted-by":"publisher","first-page":"100326","DOI":"10.1016\/j.jcpo.2022.100326","volume":"32","author":"JC Michaeli","year":"2022","unstructured":"Michaeli JC, Boch T, Albers S, Michaeli T, Michaeli DT. Socio-economic burden of disease: Survivorship costs for bladder cancer. J Cancer Policy. 2022;32:100326. https:\/\/doi.org\/10.1016\/j.jcpo.2022.100326.","journal-title":"J Cancer Policy"},{"issue":"18","key":"1648_CR2","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/BF03262330","volume":"21","author":"MF Botteman","year":"2003","unstructured":"Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21(18):1315\u201330. https:\/\/doi.org\/10.1007\/BF03262330.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1648_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"J Wan","year":"2017","unstructured":"Wan J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338. https:\/\/doi.org\/10.1038\/nrc.2017.7.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1648_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","volume":"32","author":"LA Diaz Jr","year":"2014","unstructured":"Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579\u201386. https:\/\/doi.org\/10.1200\/JCO.2012.45.2011.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1648_CR5","doi-asserted-by":"publisher","first-page":"102087","DOI":"10.1016\/j.clgc.2024.102087","volume":"22","author":"CV Suartz","year":"2024","unstructured":"Suartz CV, Martinez LM, Cordeiro MD, Botelho LAA, Gallutti FP, Mota JM, Leite KRM, Toren P, Nahas WC, Ribeiro-Filho LA. Honing the Hunt: A Comprehensive Review of Cell-free Tumor DNA to Predict Neoadjuvant Therapy Efficacy in Bladder Cancer. Clin Genitourin Cancer. 2024;22(3):102087. https:\/\/doi.org\/10.1016\/j.clgc.2024.102087.","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"1648_CR6","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3390\/cancers13061448","volume":"13","author":"R Herranz","year":"2021","unstructured":"Herranz R, Oto J, Plana E, Fern\u00e1ndez-Pardo \u00c1, Cana F, Mart\u00ednez-Sarmiento M, Vera-Donoso CD, Espa\u00f1a F, Medina P. Circulating Cell-Free DNA in Liquid Biopsies as Potential Biomarker for Bladder Cancer: A Systematic Review. Cancers (Basel). 2021;13(6):1448. https:\/\/doi.org\/10.3390\/cancers13061448.","journal-title":"Cancers (Basel)"},{"key":"1648_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15:131. https:\/\/doi.org\/10.1186\/s13045-022-01351-y.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1648_CR8","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1097\/JS9.0000000000001372","volume":"110","author":"H Liu","year":"2024","unstructured":"Liu H, Chen J, Huang Y, Zhang Y, Ni Y, Xu N, Zhao F, Tang Y, Liu H, Sun G, Shen P, Liu Z, Huang J, Liao B, Zeng H. Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis. Int J Surg. 2024;110(6):3923\u201336. https:\/\/doi.org\/10.1097\/JS9.0000000000001372.","journal-title":"Int J Surg"},{"key":"1648_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.critrevonc.2019.06.005","volume":"141","author":"G Ponti","year":"2019","unstructured":"Ponti G, Manfredini M, Tomasi A. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Crit Rev Oncol Hematol. 2019;141:36\u201342. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.06.005.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"1648_CR10","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.3390\/jcm13072057","volume":"13","author":"S Bhalla","year":"2024","unstructured":"Bhalla S, Passarelli R, Biswas A, De S, Ghodoussipour S. Plasma-derived cell-free dna as a biomarker for early detection, prognostication, and personalized treatment of urothelial carcinoma. J Clin Med. 2024;13(7):2057. https:\/\/doi.org\/10.3390\/jcm13072057.","journal-title":"J Clin Med"},{"key":"1648_CR11","doi-asserted-by":"publisher","first-page":"14707","DOI":"10.1038\/s41598-018-32900-6","volume":"8","author":"DH Lee","year":"2018","unstructured":"Lee DH, Yoon H, Park S, et al. Urinary Exosomal and cell-free DNA Detects somatic mutation and copy number alteration in urothelial carcinoma of bladder. Sci Rep. 2018;8:14707. https:\/\/doi.org\/10.1038\/s41598-018-32900-6.","journal-title":"Sci Rep"},{"issue":"14","key":"1648_CR12","doi-asserted-by":"publisher","first-page":"1171065","DOI":"10.3389\/fimmu.2023.1171065","volume":"19","author":"R Herranz","year":"2023","unstructured":"Herranz R, Oto J, Hueso M, Plana E, Cana F, Casta\u00f1o M, Cord\u00f3n L, Ramos-Soler D, Bonanad S, Vera-Donoso CD, Mart\u00ednez-Sarmiento M, Medina P. Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro. Front Immunol. 2023;19(14):1171065. https:\/\/doi.org\/10.3389\/fimmu.2023.1171065.","journal-title":"Front Immunol"},{"issue":"12","key":"1648_CR13","doi-asserted-by":"publisher","first-page":"1458362","DOI":"10.3389\/fbioe.2024.1458362","volume":"4","author":"FF Huang","year":"2024","unstructured":"Huang FF, Di XF, Bai MH. Analysis of urine cell-free DNA in bladder cancer diagnosis by emerging bioactive technologies and materials. Front Bioeng Biotechnol. 2024;4(12):1458362. https:\/\/doi.org\/10.3389\/fbioe.2024.1458362.","journal-title":"Front Bioeng Biotechnol"},{"key":"1648_CR14","doi-asserted-by":"crossref","unstructured":"Peng M, Chen C, Hulbert A, Brock MV, Yu F. Non-blood circulating tumor DNA detection in cancer. Oncotarget. 2017;8:69162\u201373. Available from: https:\/\/www.oncotarget.com\/article\/19942\/text\/","DOI":"10.18632\/oncotarget.19942"},{"key":"1648_CR15","doi-asserted-by":"publisher","first-page":"100087","DOI":"10.1016\/j.bdq.2019.100087","volume":"17","author":"AJ Bronkhorst","year":"2019","unstructured":"Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087. https:\/\/doi.org\/10.1016\/j.bdq.2019.100087.","journal-title":"Biomol Detect Quantif"},{"key":"1648_CR16","doi-asserted-by":"publisher","unstructured":"Henriksen TV, Reinert T, Christensen E, Sethi H, Birkenkamp-Demtr\u00f6der K, G\u00f6genur M, G\u00f6genur I, Zimmermann BG, Improve Study Group, Dyrskj\u00f8t L, Andersen CL. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA. Mol Oncol. 2020 Aug;14(8):1670\u20139. https:\/\/doi.org\/10.1002\/1878-0261.12729","DOI":"10.1002\/1878-0261.12729"},{"key":"1648_CR17","doi-asserted-by":"publisher","first-page":"20282","DOI":"10.1038\/s41598-018-20282-8","volume":"8","author":"E Christensen","year":"2018","unstructured":"Christensen E, Nordentoft I, Vang S, Birkenkamp-Demtr\u00f6der K, Jensen JB, Agerb\u00e6k M, Pedersen JS, Dyrskj\u00f8t L. Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. Sci Rep. 2018;8:20282. https:\/\/doi.org\/10.1038\/s41598-018-20282-8.","journal-title":"Sci Rep"},{"issue":"8","key":"1648_CR18","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/ejhg.2015.281","volume":"24","author":"FS Togneri","year":"2016","unstructured":"Togneri FS, Ward DG, Foster JM, Devall AJ, Wojtowicz P, Alyas S, Vasques FR, Oumie A, James ND, Cheng KK, Zeegers MP, Deshmukh N, O\u2019Sullivan B, Taniere P, Spink KG, McMullan DJ, Griffiths M, Bryan RT. Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. Eur J Hum Genet. 2016;24(8):1167\u201374. https:\/\/doi.org\/10.1038\/ejhg.2015.281.","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"1648_CR19","doi-asserted-by":"publisher","first-page":"e0140712","DOI":"10.1371\/journal.pone.0140712","volume":"10","author":"RB Lanman","year":"2015","unstructured":"Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, Hoon DS, Kopetz ES, Lee J, Nikolinakos PG, Baca AM, Kermani BG, Eltoukhy H, Talasaz A. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS ONE. 2015;10(10):e0140712. https:\/\/doi.org\/10.1371\/journal.pone.0140712.","journal-title":"PLoS ONE"},{"issue":"2","key":"1648_CR20","doi-asserted-by":"publisher","first-page":"e22668","DOI":"10.1002\/jcla.22668","volume":"33","author":"P Li","year":"2018","unstructured":"Li P, Ning J, Luo X, Du H, Zhang Q, Zhou G, Du Q, Ou Z, Wang L, Wang Y. New method to preserve the original proportion and integrity of urinary cell-free DNA. J Clin Lab Anal. 2018;33(2):e22668. https:\/\/doi.org\/10.1002\/jcla.22668.","journal-title":"J Clin Lab Anal"},{"issue":"7","key":"1648_CR21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1373\/clinchem.2019.306777","volume":"65","author":"THT Cheng","year":"2019","unstructured":"Cheng THT, Jiang P, Teoh JY, et al. Noninvasive detection of bladder cancer by shallow-depth genome-wide bisulfite sequencing of urinary cell-free DNA for methylation and copy number profiling. Clin Chem. 2019;65(7):927\u201336. https:\/\/doi.org\/10.1373\/clinchem.2019.306777.","journal-title":"Clin Chem"},{"issue":"18","key":"1648_CR22","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Sethi H, Shchegrova S, Salari R, Nordentoft I, Wu HT, Knudsen M, Lamy P, Lindskrog SV, Taber A, Balcioglu M, Vang S, Assaf Z, Sharma S, Tin AS, Srinivasan R, Hafez D, Reinert T, Navarro S, Dyrskj\u00f8t L. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37(18):1547\u201357. https:\/\/doi.org\/10.1200\/JCO.18.02052.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1648_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.eururo.2024.05.014","volume":"86","author":"I Nordentoft","year":"2024","unstructured":"Nordentoft I, Lindskrog SV, Birkenkamp-Demtr\u00f6der K, Gonzalez S, Kuzman M, Levatic J, Glavas D, Ptashkin R, Smadbeck J, Afterman D, Lauterman T, Cohen Y, Donenhirsh Z, Tavassoly I, Alon U, Frydendahl A, Rasmussen MH, Andersen CL, Lamy P, Dyrskj\u00f8t L. Whole-genome mutational analysis for tumor-informed detection of circulating tumor DNA in patients with urothelial carcinoma. Eur Urol. 2024;86(4):301\u201311. https:\/\/doi.org\/10.1016\/j.eururo.2024.05.014.","journal-title":"Eur Urol"},{"key":"1648_CR24","doi-asserted-by":"publisher","unstructured":"Baer C, Kern W, Koch S, Nadarajah N, Schindela S, Meggendorfer M, et al. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia [Internet]. Vol. 101, Haematologica. Ferrata Storti Foundation (Haematologica); 2016. p. 830\u20138. Available from: https:\/\/doi.org\/10.3324\/haematol.2016.145888","DOI":"10.3324\/haematol.2016.145888"},{"key":"1648_CR25","doi-asserted-by":"publisher","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors [Internet]. Vol. 8, Nature Communications. Springer Science and Business Media LLC; 2017. Available from: https:\/\/doi.org\/10.1038\/s41467-017-00965-y","DOI":"10.1038\/s41467-017-00965-y"},{"key":"1648_CR26","unstructured":"Treatment of Metastatic Bladder Cancer at the Time of Biochemical reLApse Following Radical Cystectomy - Full Text View - ClinicalTrials.gov [Internet]. [cited 2023 Dec 18]. Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04138628"},{"issue":"2","key":"1648_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3892\/or.18.2.405","volume":"18","author":"T Szarvas","year":"2007","unstructured":"Szarvas T, Kovalszky I, Bedi K, Szendroi A, Majoros A, Riesz P, F\u00fcle T, L\u00e1szl\u00f3 V, Kiss A, Romics I. Deletion analysis of tumor and urinary DNA to detect bladder cancer: Urine supernatant versus urine sediment. Oncol Rep. 2007;18(2):405\u201310. https:\/\/doi.org\/10.3892\/or.18.2.405.","journal-title":"Oncol Rep"},{"issue":"1","key":"1648_CR28","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.clgc.2014.07.010","volume":"13","author":"SZ Millis","year":"2015","unstructured":"Millis SZ, Bryant D, Basu G, Bender R, Vranic S, Gatalica Z, Vogelzang NJ. Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clin Genitourin Cancer. 2015;13(1):e37-49. https:\/\/doi.org\/10.1016\/j.clgc.2014.07.010.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"1648_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3233\/blc-170152","volume":"4","author":"IJ Russo","year":"2018","unstructured":"Russo IJ, Ju Y, Gordon NS, Zeegers MP, Cheng KK, James ND, Bryan RT, Ward DG. Toward personalised liquid biopsies for urothelial carcinoma: Characterisation of ddPCR and urinary cfDNA for the detection of the TERT 228 GA\/T mutation. Bladder Cancer. 2018;4(1):41\u20138. https:\/\/doi.org\/10.3233\/blc-170152.","journal-title":"Bladder Cancer"},{"issue":"6","key":"1648_CR30","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","volume":"71","author":"E Christensen","year":"2017","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Nordentoft I, H\u00f8yer S, van der Keur K, van Kessel K, Zwarthoff E, Agerb\u00e6k M, \u00d8rntoft TF, Jensen JB, Dyrskj\u00f8t L. Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur Urol. 2017;71(6):961\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.016.","journal-title":"Eur Urol"},{"issue":"3","key":"1648_CR31","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/bju.14808","volume":"124","author":"DG Ward","year":"2019","unstructured":"Ward DG, Gordon NS, Boucher RH, Pirrie SJ, Baxter L, Ott S, Silcock L, Whalley CM, Stockton JD, Beggs AD, Griffiths M, Abbotts B, Ijakipour H, Latheef FN, Robinson RA, White AJ, James ND, Zeegers MP, Cheng KK, Bryan RT. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: A 23-gene panel with utility for non-invasive diagnosis and risk stratification. BJU Int. 2019;124(3):532\u201344. https:\/\/doi.org\/10.1111\/bju.14808.","journal-title":"BJU Int"},{"issue":"3","key":"1648_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.hoc.2021.02.004","volume":"35","author":"H Ahmadi","year":"2021","unstructured":"Ahmadi H, Duddalwar V, Daneshmand S. Diagnosis and staging of bladder cancer. Hematol Oncol Clin North Am. 2021;35(3):531\u201341. https:\/\/doi.org\/10.1016\/j.hoc.2021.02.004.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"1648_CR33","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1053\/hupa.2001.24999","volume":"32","author":"SJ Cina","year":"2001","unstructured":"Cina SJ, Epstein JI, Endrizzi JM, Harmon WJ, Seay TM, Schoenberg MP. Correlation of cystoscopic impression with histologic diagnosis of biopsy specimens of the bladder. Hum Pathol. 2001;32(6):630\u20137. https:\/\/doi.org\/10.1053\/hupa.2001.24999.","journal-title":"Hum Pathol"},{"issue":"2","key":"1648_CR34","doi-asserted-by":"publisher","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","volume":"33","author":"FA Yafi","year":"2015","unstructured":"Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015;33(2):66.e25-e31. https:\/\/doi.org\/10.1016\/j.urolonc.2014.06.008.","journal-title":"Urol Oncol"},{"issue":"2","key":"1648_CR35","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/jcmm.14042","volume":"23","author":"S Zhang","year":"2019","unstructured":"Zhang S, Du L, Wang L, Jiang X, Zhan Y, Li J, Yan K, Duan W, Zhao Y, Wang L, Wang Y, Shi Y, Wang C. Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer. J Cell Mol Med. 2019;23(2):1396\u2013405. https:\/\/doi.org\/10.1111\/jcmm.14042.","journal-title":"J Cell Mol Med"},{"issue":"11","key":"1648_CR36","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/cncr.31375","volume":"124","author":"N Agarwal","year":"2018","unstructured":"Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, et al. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018;124(11):2115\u201324. https:\/\/doi.org\/10.1002\/cncr.31375.","journal-title":"Cancer"},{"issue":"4","key":"1648_CR37","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","volume":"73","author":"K Birkenkamp-Demtr\u00f6der","year":"2018","unstructured":"Birkenkamp-Demtr\u00f6der K, Christensen E, Nordentoft I, Knudsen M, Taber A, H\u00f8yer S, Lamy P, Agerb\u00e6k M, Jensen JB, Dyrskj\u00f8t L. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur Urol. 2018;73(4):535\u201340. https:\/\/doi.org\/10.1016\/j.eururo.2017.09.011.","journal-title":"Eur Urol"},{"issue":"23","key":"1648_CR38","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","volume":"29","author":"SV Lindskrog","year":"2023","unstructured":"Lindskrog SV, Birkenkamp-Demtr\u00f6der K, Nordentoft I, Laliotis G, Lamy P, Christensen E, Renner D, Andreasen TG, Lange N, Sharma S, ElNaggar AC, Liu MC, Sethi H, Aleshin A, Agerb\u00e6k M, Jensen JB, Dyrskj\u00f8t L. Circulating tumor DNA analysis in advanced urothelial carcinoma: Insights from biological analysis and extended clinical follow-up. Clin Cancer Res. 2023;29(23):4797\u2013807. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1860.","journal-title":"Clin Cancer Res"},{"key":"1648_CR39","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados B, Kockx M, Assaf ZJ, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022;82:212\u201322.","journal-title":"Eur Urol"},{"key":"1648_CR40","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-020-03210-3","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595:432\u20137. https:\/\/doi.org\/10.1038\/s41586-020-03210-3.","journal-title":"Nature"},{"key":"1648_CR41","doi-asserted-by":"publisher","unstructured":"Zviran A, Schulman RC, Shah M, Hill STK, Deochand S, Khamnei CC, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring [Internet]. Vol. 26, Nature Medicine. Springer Science and Business Media LLC; 2020. p. 1114\u201324. Available from: https:\/\/doi.org\/10.1038\/s41591-020-0915-3","DOI":"10.1038\/s41591-020-0915-3"},{"key":"1648_CR42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2217\/fon-2022-0868","volume":"19","author":"F Jackson-Spence","year":"2023","unstructured":"Jackson-Spence F, Toms C, O\u2019Mahony LF, et al. IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future Oncol. 2023;19:509\u201315. https:\/\/doi.org\/10.2217\/fon-2022-0868.","journal-title":"Future Oncol"},{"key":"1648_CR43","unstructured":"Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study [Internet]. [cited 2023 Dec 18]. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05987241"},{"issue":"5","key":"1648_CR44","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/JU.0000000000001863","volume":"206","author":"R Zhang","year":"2021","unstructured":"Zhang R, Zang J, Xie F, et al. Urinary molecular pathology for patients with newly diagnosed urothelial bladder cancer. J Urol. 2021;206(5):873\u201384. https:\/\/doi.org\/10.1097\/JU.0000000000001863.","journal-title":"J Urol"},{"issue":"11","key":"1648_CR45","doi-asserted-by":"publisher","first-page":"e1003732","DOI":"10.1371\/journal.pmed.1003732","volume":"18","author":"PS Chauhan","year":"2021","unstructured":"Chauhan PS, Chen K, Babbra RK, et al. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: a cohort study. PLoS Med. 2021;18(11):e1003732. https:\/\/doi.org\/10.1371\/journal.pmed.1003732.","journal-title":"PLoS Med"},{"issue":"11","key":"1648_CR46","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1002\/1878-0261.13639","volume":"18","author":"HM Vedeld","year":"2024","unstructured":"Vedeld HM, Pharo H, S\u00f8rb\u00f8 AK, et al. Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer. Mol Oncol. 2024;18(11):2684\u201395. https:\/\/doi.org\/10.1002\/1878-0261.13639.","journal-title":"Mol Oncol"},{"issue":"2","key":"1648_CR47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.urolonc.2018.10.023","volume":"37","author":"Y Xu","year":"2019","unstructured":"Xu Y, Kim YH, Jeong P, et al. Diagnostic value of combined IQGAP3\/BMP4 and IQGAP3\/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urol Oncol. 2019;37(2):86\u201396. https:\/\/doi.org\/10.1016\/j.urolonc.2018.10.023.","journal-title":"Urol Oncol"},{"key":"1648_CR48","doi-asserted-by":"publisher","first-page":"597486","DOI":"10.3389\/fonc.2020.597486","volume":"10","author":"Y Xu","year":"2020","unstructured":"Xu Y, Ma X, Ai X, et al. A urine-based liquid biopsy method for detection of upper tract urinary carcinoma. Front Oncol. 2020;10:597486. https:\/\/doi.org\/10.3389\/fonc.2020.597486.","journal-title":"Front Oncol"},{"issue":"9","key":"1648_CR49","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","volume":"32","author":"EA Klein","year":"2021","unstructured":"Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167\u201377. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.806.","journal-title":"Ann Oncol"},{"issue":"19","key":"1648_CR50","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, et al. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. 2024;391(19):1773\u201386. https:\/\/doi.org\/10.1056\/NEJMoa2408154.","journal-title":"N Engl J Med"},{"issue":"3","key":"1648_CR51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3233\/BLC-230105","volume":"10","author":"TF Stewart","year":"2024","unstructured":"Stewart TF, Chalfin H, Simon N, Tan A, Apolo A, McKay RR. Perioperative use of ctDNA to guide treatment for urothelial carcinoma: The future is now. Bladder Cancer. 2024;10(3):183\u201398. https:\/\/doi.org\/10.3233\/BLC-230105.","journal-title":"Bladder Cancer"},{"issue":"1","key":"1648_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euo.2023.05.012","volume":"7","author":"E Crupi","year":"2024","unstructured":"Crupi E, de Padua TC, Marandino L, et al. Circulating tumor DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer: A systematic review. Eur Urol Oncol. 2024;7(1):44\u201352. https:\/\/doi.org\/10.1016\/j.euo.2023.05.012.","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"1648_CR53","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1158\/1940-6207.CAPR-16-0113","volume":"9","author":"M Puntoni","year":"2016","unstructured":"Puntoni M, Petrera M, Campora S, et al. Prognostic significance of VEGF after twenty-year follow-up in a randomized trial of fenretinide in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila). 2016;9(6):437\u201344. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-16-0113.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"3","key":"1648_CR54","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41416-021-01487-z","volume":"126","author":"KS Shohdy","year":"2022","unstructured":"Shohdy KS, Villamar DM, Cao Y, et al. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. Br J Cancer. 2022;126(3):430\u20139. https:\/\/doi.org\/10.1038\/s41416-021-01487-z.","journal-title":"Br J Cancer"},{"issue":"5","key":"1648_CR55","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.euo.2020.02.002","volume":"3","author":"P Grivas","year":"2020","unstructured":"Grivas P, Lalani AA, Pond GR, et al. Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: A pilot study. Eur Urol Oncol. 2020;3(5):695\u20139. https:\/\/doi.org\/10.1016\/j.euo.2020.02.002.","journal-title":"Eur Urol Oncol"},{"issue":"10031","key":"1648_CR56","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00513-X","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(16)00513-X.","journal-title":"Lancet"},{"issue":"1","key":"1648_CR57","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41467-020-20626-5","volume":"12","author":"G Vandekerkhove","year":"2021","unstructured":"Vandekerkhove G, Lavoie J-M, Annala M, et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun. 2021;12(1):184. https:\/\/doi.org\/10.1038\/s41467-020-20626-5.","journal-title":"Nat Commun"},{"issue":"7","key":"1648_CR58","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3917","volume":"29","author":"E Christensen","year":"2023","unstructured":"Christensen E, Nordentoft I, Birkenkamp-Demtr\u00f6der K, et al. Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer. Clin Cancer Res. 2023;29(7):1582\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3917.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1648_CR59","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/path.5886","volume":"261","author":"J Zang","year":"2023","unstructured":"Zang J, Zhang R, Jin D, et al. Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial. J Pathol. 2023;261(2):198\u2013209. https:\/\/doi.org\/10.1002\/path.5886.","journal-title":"J Pathol"},{"issue":"1","key":"1648_CR60","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2015.12.045","volume":"70","author":"K Birkenkamp-Demtr\u00f6der","year":"2016","unstructured":"Birkenkamp-Demtr\u00f6der K, Nordentoft I, Christensen E, et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol. 2016;70(1):75\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2015.12.045.","journal-title":"Eur Urol"},{"issue":"4","key":"1648_CR61","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","volume":"9","author":"JC Dudley","year":"2019","unstructured":"Dudley JC, Schroers-Martin J, Lazzareschi DV, et al. Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discov. 2019;9(4):500\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0825.","journal-title":"Cancer Discov"},{"issue":"15","key":"1648_CR62","doi-asserted-by":"publisher","first-page":"16578","DOI":"10.3390\/ijms241516578","volume":"24","author":"R Carrasco","year":"2023","unstructured":"Carrasco R, Ingelmo-Torres M, Trullas R, et al. Tumor-agnostic circulating tumor DNA testing for monitoring muscle-invasive bladder cancer. Int J Mol Sci. 2023;24(15):16578. https:\/\/doi.org\/10.3390\/ijms241516578.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1648_CR63","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s11912-024-01555-0","volume":"26","author":"JA Linscott","year":"2024","unstructured":"Linscott JA, Miyagi H, Murthy PB, Yao S, Grass GD, Vosoughi A, Xu H, Wang X, Yu X, Yu A, Zemp L, Gilbert SM, Poch MA, Sexton WJ, Spiess PE, Li R. From detection to cure - Emerging roles for urinary tumor DNA (utDNA) in bladder cancer. Curr Oncol Rep. 2024;26(8):945\u201358. https:\/\/doi.org\/10.1007\/s11912-024-01555-0.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"1648_CR64","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012.","journal-title":"Ann Oncol"},{"issue":"2","key":"1648_CR65","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","volume":"23","author":"AO Siefker-Radtke","year":"2022","unstructured":"Siefker-Radtke AO, Necchi A, Park SH, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022;23(2):248\u201358. https:\/\/doi.org\/10.1016\/S1470-2045(21)00660-4.","journal-title":"Lancet Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01648-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01648-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01648-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T15:38:19Z","timestamp":1743521899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01648-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1648"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01648-4","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"31 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors report no relationships that could be construed as a conflict of interest. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}